Envisioning the Future of Ocular Therapeutics
About Us | Unmet Needs | Technologies | Product Pipeline | Media & Investors
Product Pipeline


Our own products will focus on innovative therapeutics based on our technologies and off-patent drugs (drugs whose patent has expired). Our basic strategy is to combine our technology with the off-patent drugs to get FDA approval in an accelerated manner. This will allow our superior product to reach those who need or want non-invasive treatments faster. For certain high-demand drugs that treat immediate sight threatening diseases, Aciontís products may be eligible for fast-track FDA approvals.

Aciont® plans to partner with leading pharmaceutical companies involved with ocular therapeutics who may need our technology to deliver their drugs, or who may want to help us market our own products currently in development.